GSK's Augmentin is India's no.1 drug brand

Research firm PharmaTrac data shows Augmentin sales at Rs 801 crore from November 2022-23. For the month of November, Augmentin sales stood at Rs 75 crore. It has shown a moving annual total (MAT) growth growth of 12.3%. As per the data, Glycomet GP sales stood at Rs 774 crore from same period and the sales for November stood at Rs 64 crore. It has shown a MAT growth of 7.5%.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news